You are here

Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AR053395-01
Agency Tracking Number: AR053395
Amount: $100,074.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
ELSOHLY LABORATORIES, INC. (ELI) 5 INDUSTRIAL PARK DR
OXFORD, MS 38655
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MAHMOUD ELSOHLY
 (662) 236-2609
 elsohly@elsohly.com
Business Contact
 MAHMOUD ELSOHLY
Phone: (662) 236-2609
Email: ELSOHLY@ELSOHLY.COM
Research Institution
 UNIVERSITY OF MISSISSIPPI
 
UNIVERSITY OF MISSISSIPPI 125 OLD CHEMISTRY
UNIVERSITY, MS 38677
United States

 Nonprofit College or University
Abstract

DESCRIPTION (provided by applicant): The long term objectives of this proposal are aimed at the development of new composition(s) to be used for the prophylactic treatment/prevention of poison ivy contact dermatitis in sensitive individuals. Poison ivy/poison oak and another related species poison sumac are the main cause of occupational hazards for outdoor workers in the United States. Most of the products on the market today are aimed at applying a chemical barrier prior to being exposed to these plants or directed toward symptomatic treatment of the dermatitis. The products proposed in this application will be directed towards treatment of individuals who have never been exposed to poison ivy and therefore inducing tolerance in these individuals (equivalent to immunization) and/or towards prophylactic treatment of already sensitive individuals, perhaps using a single injection prior to each season. The aims, therefore of this proposal will be to prepare (synthesize) different derivatives with enhanced physical and formulation characteristics, testing of these products (or at least one selected agent) in the guinea pig animal model for efficacy as a proof of concept. The results of this work will form the basis for a Phase II application directed toward optimization of formulation, dosage and route of administration as well as carrying out stability, pharmacokinetics and preclinical toxicology/developmental activities. This proposal addresses a major public health problem, namely contact allergic dermatitis and promises the development of an effective agent to address this problem.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government